EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

EZH2 in non-cancerous diseases: expanding horizons

Renjing Jin iD, Jianlin Zhang, Yuqing Wang, Ziyu Chen, Xuan He, Xintong Zhang, Zhen Tan, Celina G Kleer, Ye Li, Deli Wang, Lixiang Xue

Protein & Cell · 15.05.2025

DOI: 10.1093/procel/pwaf032 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Protein & Cell, online erschienen am 15.05.2025. Verfasst von Renjing Jin und 10 weiteren Autor:innen. Beteiligte Einrichtung: Peking University Third Hospital Cancer Center, Peking University Third Hospital, Beijing 100191, China. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 179 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Enhancer of Zeste homolog 2 (EZH2), a histone methyltransferase within polycomb repressive complex 2 (PRC2), plays a crucial role in epigenetic regulation by silencing gene expression through trimethylation of histone 3 at lysine 27 (H3K27me3). Beyond its well-documented oncogenic functions, emerging research has revealed EZH2’s involvement in various non-cancerous pathologies. For instance, EZH2 is critical in regulating immune responses, particularly in modulating T cell differentiation and cytokine production, which affects inflammation and immune homeostasis. EZH2 also controls fibroblast activation and extracellular matrix (ECM) remodeling, influencing critical processes such as cell differentiation, tissue repair and energy homeostasis. Additionally, EZH2’s epigenetic regulation of neuroinflammatory processes is linked to neuronal health and survival. Recent advancements in EZH2 inhibitor therapies demonstrate promising potential for treating a range of non-cancerous conditions, with preclinical trials suggesting efficacy in mitigating disease progression. This review highlights the expanding functional scope of EZH2, emphasizing its epigenetic mechanisms and the therapeutic opportunities for targeting EZH2 in non-cancerous diseases.

Schlagwörter

Stichwörter der Autor:innen

EZH2EZH2 inhibitordegenerative diseasefibrosisimmunological disordernon-cancerous disease

Autor:innen und Institutionen

  • Peking University Third Hospital Cancer Center, Peking University Third Hospital, Beijing 100191, China.
  • Center of Basic Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing 100191, China.
  • Beijing Key Laboratory of Interdisciplinary Research in Gastrointestinal Oncology (BLGO), Peking University Third Hospital, Beijing 100191, China.
  • Department of Bone and Joint Surgery, Peking University Shenzhen Hospital, Shenzhen 518036, China.
  • Department of Orthopaedics, Peking University Third Hospital, Beijing, 100191, CN.
  • Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, 48109, United States.

ORCID-Profile: Renjing Jin

Zitieren

APA

Jin, R., Zhang, J., Wang, Y., Chen, Z., He, X., Zhang, X., Tan, Z., Kleer, C. G., Li, Y., Wang, D., & Xue, L. (2025). EZH2 in non-cancerous diseases: expanding horizons. Protein & Cell. https://doi.org/10.1093/procel/pwaf032

Vancouver

Jin R, Zhang J, Wang Y, Chen Z, He X, Zhang X, et al. EZH2 in non-cancerous diseases: expanding horizons. Protein & Cell. 2025. doi:10.1093/procel/pwaf032

BibTeX
@article{Jin2025,
  author = {Jin, Renjing and Zhang, Jianlin and Wang, Yuqing and Chen, Ziyu and He, Xuan and Zhang, Xintong and Tan, Zhen and Kleer, Celina G and Li, Ye and Wang, Deli and Xue, Lixiang},
  title = {EZH2 in non-cancerous diseases: expanding horizons},
  journal = {Protein & Cell},
  year = {2025},
  doi = {10.1093/procel/pwaf032}
}
Kostenlos starten →